BioTools Joins Chiral Technologies in Cooperative Agreement
BioTools Inc., of Jupiter Florida, and Chiral Technologies Inc., of West Chester, Pennsylvania, have entered into a cooperative agreement that will provide comprehensive coverage of chirality-related services and technologies ranging from small scale and preparative chromatography to absolute configuration of chiral compounds.
BioTools Inc., of Jupiter Florida, and Chiral Technologies Inc., of West Chester, Pennsylvania, have entered into a cooperative agreement that will provide comprehensive coverage of chirality-related services and technologies ranging from small scale and preparative chromatography to absolute configuration of chiral compounds. The combination of services from the two companies is expected to improve efficiency and understanding in a range of research areas such as drug discovery, drug development, and industrial process.
Although the scope of the agreement has not yet been disclosed, Rina Dukor, president of BioTools said “Entering into this collaborative alliance with Chiral Technologies will provide researchers with a unique blend of services, instruments and technologies to advance the understanding that chiral-based structures play in biological and chemical processes.”
BioTools provides advanced chiroptical instrumentation and services to pharmaceutical companies and academia serving critical areas of biopharmaceutical and chiral drugs research. Chiral Technologies supplies chiral chromatography products and services in North and South America.
New TRC Facility Accelerates Innovation and Delivery
April 25th 2025We’ve expanded our capabilities with a state-of-the-art, 200,000 sq ft TRC facility in Toronto, completed in 2024 and staffed by over 100 PhD- and MSc-level scientists. This investment enables the development of more innovative compounds, a broader catalogue and custom offering, and streamlined operations for faster delivery. • Our extensive range of over 100,000 high-quality research chemicals—including APIs, metabolites, and impurities in both native and stable isotope-labelled forms—provides essential tools for uncovering molecular disease mechanisms and exploring new opportunities for therapeutic intervention.
New Guide: Characterising Impurity Standards – What Defines “Good Enough?”
April 25th 2025Impurity reference standards (IRSs) are essential for accurately identifying and quantifying impurities in pharmaceutical development and manufacturing. Yet, with limited regulatory guidance on how much characterisation is truly required for different applications, selecting the right standard can be challenging. To help, LGC has developed a new interactive multimedia guide, packed with expert insights to support your decision-making and give you greater confidence when choosing the right IRS for your specific needs.
